St Charles Pharma receives SBIR grant from National Institutes of Health

This substantial award will fund the work necessary to bring the company’s neuropathic pain treatment, SCP-123, from the laboratory to the clinic, including the preparation of the investigational new drug application that will be submitted to the FDA.

Kenneth Narducy, president of St Charles, said: “This relatively new National Institute of Neurological Disorders and Stroke (NINDS) program helps small companies bridge the gap between the research lab and human clinical studies. St Charles will also benefit from the cooperative aspect of this grant because we will have a higher level of involvement with NINDS staff compared to typical SBIR grants.”